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Abstract 
Background: Treatment of patients with type 2 diabetes mellitus (T2DM) and a history of cardiovascular (CV) disease 
or CV risk factors may present clinical challenges due to the presence of comorbid conditions and the use of concom-
itant medications. The sodium glucose co-transporter 2 inhibitor, canagliflozin, has been shown to improve glycae-
mic control and reduce body weight and blood pressure (BP) with a favourable tolerability profile in a broad range 
of patients with T2DM. This post hoc analysis assessed the efficacy and safety of canagliflozin in patients with T2DM 
based on CV disease history or CV risk factors.
Methods: Analyses were based on pooled data from four 26-week, placebo-controlled, Phase 3 studies that evalu-
ated canagliflozin 100 and 300 mg in patients with T2DM (N = 2313; mean HbA1c, 8.0%; body weight, 89 kg; systolic 
BP, 128 mmHg). Changes from baseline to week 26 in HbA1c, body weight, and systolic BP were assessed based on 
history of CV disease, history of hypertension, baseline statin use, and number of CV risk factors. Safety was assessed 
based on adverse event (AE) reports.
Results: At week 26, both canagliflozin doses lowered HbA1c, body weight, and systolic BP compared with placebo 
in patients with and without CV disease history or risk factors. Placebo-subtracted HbA1c reductions with canagliflo-
zin 100 and 300 mg were similar in patients with a history of CV disease (−0.95 and −1.07%) versus no history of CV 
disease (−0.71 and −0.90%), history of hypertension (−0.72 and −0.89%) versus no history of hypertension (−0.73 
and −0.95%), baseline statin use (−0.77 and −0.99%) versus no statin use (−0.69 and −0.85%), and 0–1 CV risk factor 
(−0.72 and −0.87%) versus ≥2 CV risk factors (−0.74 and −1.02%). Similar body weight and systolic BP reductions 
were seen with canagliflozin versus placebo across subgroups. The incidence of AEs, AEs leading to discontinuation, 
and serious AEs was similar across subgroups.
Conclusions: The efficacy and safety of canagliflozin were generally consistent across subgroups of patients with 
T2DM and varying degrees of CV disease history or risk factors.
Trial registration numbers and dates ClinicalTrials.gov: NCT01081834, 4 March 2010; NCT01106625, 1 April 2010; 
NCT01106677, 1 April 2010; NCT01106690, 1 April 2010
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Background
Type 2 diabetes mellitus (T2DM) affects roughly 400 
million adults across the globe and contributes to 5 mil-
lion deaths annually [1]. The majority of these deaths 
are a result of cardiovascular (CV) complications, which 
are very common in patients with T2DM due to poorly 
controlled chronic hyperglycaemia and reduced insulin 
sensitivity [2–4]. Other major contributors to increased 
CV risk in patients with T2DM include comorbid condi-
tions such as hypertension and dyslipidaemia [5, 6]. The 
presence of these comorbid conditions and the associ-
ated requirements for concomitant medication use can 
present significant clinical challenges in the treatment of 
patients with T2DM and a history of CV disease or CV 
risk factors [7, 8].
Some pharmacologic agents may not be suitable for 
patients with T2DM and existing CV disease or CV risk 
factors. For instance, the prescribing information for the 
sulphonylureas glipizide [9] and glyburide [10] include 
a warning for increased risk of CV death, and the pre-
scribing information for pioglitazone includes a warning 
for congestive heart failure [11]. Additionally, guidelines 
from the American Diabetes Association recommend 
against the use of agents associated with hypoglycaemia 
in patients with T2DM and coronary artery disease [7]. 
Overall, there remains a need for antihyperglycaemic 
agents (AHAs) that are efficacious and well tolerated 
in people with T2DM and CV disease history/risk fac-
tors; ideally, such medications would provide not only 
improved glycaemic control but also favourable effects 
on CV risk factors such as body weight, hypertension, 
and dyslipidaemia.
Canagliflozin is a sodium glucose co-transporter 2 
(SGLT2) inhibitor approved for the treatment of adults 
with T2DM. Canagliflozin lowers the renal threshold 
for glucose, thereby promoting urinary glucose excre-
tion (UGE) and resulting in a mild osmotic diuresis and 
a net caloric loss [12, 13]. The mechanism of action for 
canagliflozin is independent of insulin and is comple-
mentary to other AHAs, with a low inherent risk for 
hypoglycaemia. Across Phase 3 clinical trials, canagli-
flozin has been shown to provide improvements in gly-
caemic control as well as reductions in body weight and 
blood pressure (BP) as monotherapy and in combination 
with other AHAs in a broad range of patients with T2DM 
[14].
In this analysis, the efficacy and safety of canagliflozin 
was assessed among patients with T2DM in subgroups 
based on CV disease history and CV risk factors using 
pooled data from four 26-week, placebo-controlled, 
Phase 3 studies [15–18].
Methods
Patients and study design
These post hoc analyses were based on pooled data from 
four 26-week, randomised, placebo-controlled, Phase 3 
studies of canagliflozin 100 and 300 mg in patients with 
T2DM. These studies included evaluation of canagliflo-
zin compared with placebo as monotherapy in patients 
with T2DM inadequately controlled with diet and exer-
cise (ClinicalTrials.gov Identifier: NCT01081834) [15], 
and as combination therapy in patients on background 
metformin (NCT01106677) [16], metformin plus sul-
phonylurea (NCT01106625) [17], and metformin plus 
pioglitazone (NCT01106690) [18]. In all studies, patients 
were randomised to receive canagliflozin 100 or 300 mg 
or placebo once daily during a 26-week, double-blind, 
core treatment period, followed by a 26-week exten-
sion period. Data from the 26-week core treatment peri-
ods of each study were included in this pooled analysis. 
The high glycaemic subset (HbA1c >10 and ≤12.0%) of 
the monotherapy study [15] was not placebo controlled, 
and the sitagliptin arm of the add-on to metformin study 
[16] was not prespecified for efficacy comparisons ver-
sus canagliflozin at week 26; therefore, these populations 
were excluded from the analysis.
Table 1 Study design and patient population
Data have been previously reported [19, 22, 24]
eGFR estimated glomerular filtration rate, PBO placebo, CANA canagliflozin, MET metformin, SU sulphonylurea, PIO pioglitazone
Study Inclusion criteria Patients contributing data to  
pooled analysis, n





Monotherapy 18–80 7.0–10.0 ≥50 192 195 197 584
Add-on to MET 18–80 7.0–10.5 ≥55 183 368 367 918
Add-on to MET + SU 18–80 7.0–10.5 ≥55 156 157 156 469
Add-on to MET + PIO 18–80 7.0–10.5 ≥55 115 113 114 342
Overall total, N 646 833 834 2313
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Key inclusion criteria for these studies are summarised 
in Table 1. Key exclusion criteria common to all studies 
included repeated fasting plasma glucose (FPG) generally 
≥15.0 mmol/L during the pretreatment phase; history of 
diabetic ketoacidosis or type 1 diabetes; history of myo-
cardial infarction, unstable angina, revascularisation pro-
cedure, or cerebrovascular accident within 3  months of 
screening; uncontrolled hypertension; and alanine ami-
notransferase level >2 times the upper limit or normal 
or total bilirubin >1.5 times the upper limit of normal at 
screening [19].
Details of the individual study designs have been pre-
viously reported [15–18]. Briefly, in each study, eligible 
patients who were on protocol-specified background 
AHA treatment entered into a 2-week, placebo run-
in period. Patients who were not on protocol-specified 
background AHA treatment (n = 821; 35.5%) entered an 
8- to 12-week adjustment/dose stabilisation period prior 
to the placebo run-in period. After the placebo run-in 
period, patients were randomised (1:1:1) to canagliflo-
zin 100 or 300 mg or placebo. Glycaemic rescue therapy 
using an AHA that was complementary to the protocol-
specified background therapy was initiated using proto-
col-specified FPG criteria.
All studies were conducted in accordance with ethical 
principles originating in the Declaration of Helsinki and 
were consistent with Good Clinical Practices and appli-
cable regulatory requirements. Approval was obtained 
from institutional review boards and independent eth-
ics committees for participating centres, and written 
informed consent was provided by all patients prior to 
participation.
Study endpoints and assessments
For this post hoc analysis, data from patients who 
received canagliflozin 100 or 300 mg or placebo in these 
four clinical trials were pooled and analysed in four dif-
ferent subgroups: (1) history of CV disease (yes/no); (2) 
history of hypertension (yes/no); (3) statin use at baseline 
(yes/no); and (4) number of CV risk factors at baseline 
(0–1 or ≥2), defined as current cigarette smoker, T2DM 
history of ≥10  years, baseline high-density lipoprotein 
cholesterol (HDL-C) of <39  mg/dL, micro- or macro-
albuminuria (i.e., baseline albumin to creatinine ratio of 
≥30 mg/g), and screening systolic BP >140 mmHg. The 
terms used to define history of CV disease or history of 
hypertension and statin use at baseline are provided in 
Additional file  1. Efficacy endpoints assessed at week 
26 for each subgroup included changes from baseline in 
HbA1c, body weight, and systolic BP. Safety assessments 
across subgroups included overall incidence of adverse 
events (AEs), AEs leading to discontinuation, AEs related 
to study drug, serious AEs, and deaths.
Statistical analyses
All analyses used data from the modified intent-to-treat 
(mITT) population from each study, which consisted of 
all randomised patients who received ≥1 dose of double-
blind study drug. Missing data at week 26 were imputed 
using the last observation carried forward (LOCF). For 
patients who received glycaemic rescue therapy, the last 
post-baseline value prior to the initiation of rescue ther-
apy was used for efficacy analyses. Efficacy endpoints 
were assessed using an analysis of covariance (ANCOVA) 
model, with treatment and study factors and the repre-
sentative baseline value as a covariate. Least squares (LS) 
means and 95% confidence intervals (CIs) were estimated 
for comparisons of each canagliflozin dose with placebo. 
Statistical testing of canagliflozin versus placebo was not 
prespecified for analyses of efficacy parameters in these 
post hoc analyses. Therefore, no P values are reported; 
however, 95% CIs are provided for descriptive purposes.
Results
Patients
A total of 2313 patients were included in the mITT popu-
lation; of these, 155 patients (6.7%) had a history of CV 
disease, 1433 (62.0%) had a history of hypertension, and 
945 (40.9%) were using statins at baseline; 1727 patients 
(74.7%) had 0 or 1 CV risk factor and 586 (25.3%) had 
≥2 CV risk factors. In the overall population, patient 
Table 2 Baseline demographic and disease characteristics 
(overall population)
Data have been previously reported [19, 22, 24]
PBO placebo, CANA canagliflozin, BP blood pressure, eGFR estimated glomerular 
filtration rate, T2DM type 2 diabetes mellitus, SD standard deviation
a Data are mean (SD) unless otherwise indicated
b Includes American Indian or Alaska Native, Native Hawaiian or other Pacific 








 Male 334 (52) 408 (49) 404 (48)
 Female 312 (48) 425 (51) 430 (52)
Age, years 56.3 (9.8) 55.9 (10.1) 55.7 (9.5)
Race, n (%)
 White 470 (73) 591 (71) 610 (73)
 Black or African 
American
28 (4) 43 (5) 48 (6)
 Asian 82 (13) 103 (12) 100 (12)
 Otherb 66 (10) 96 (12) 76 (9)
HbA1c, % 8.0 (0.9) 8.0 (0.9) 8.0 (1.0)
Body weight, kg 89.3 (21.7) 89.8 (22.3) 88.5 (22.0)
Systolic BP, mmHg 128.2 (13.3) 128.0 (12.8) 128.8 (12.8)
eGFR, mL/min/1.73 m2 87.0 (19.8) 88.3 (19.0) 88.8 (18.9)
Duration of T2DM, years 7.5 (6.2) 7.2 (5.8) 7.4 (6.2)
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demographic and disease characteristics were gener-
ally balanced across treatment groups (Table 2). Baseline 
HbA1c, body weight, and systolic BP values in subgroups 
by CV disease history or CV risk factors are shown in 
Figs. 1, 2, 3. Generally, patients in the higher CV risk sub-
groups had higher baseline body weight and systolic BP 
values.
Efficacy
As shown in Fig. 1, LS mean changes in HbA1c from baseline 
to week 26 were greater with canagliflozin 100 and 300 mg 
than with placebo in all subgroups. Placebo-subtracted 
reductions in HbA1c were similar across subgroups, regard-
less of the presence or absence of history of CV disease or 
history of hypertension, baseline statin use, or 0–1 versus ≥2 
a b
c d
Fig. 1 Change from baseline in HbA1c at week 26. a History of CV disease, b history of hypertension, c baseline statin use, d number of CV risk  
factors. CV cardiovascular, LS least squares, SE standard error, CI confidence interval, PBO placebo, CANA canagliflozin
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CV risk factors. LS mean changes in body weight (Fig. 2) and 
systolic BP (Fig. 3) from baseline to week 26 were also greater 
with canagliflozin 100 and 300 mg than with placebo in all 
subgroups. Placebo-subtracted reductions in body weight 
were similar across subgroups, regardless of the presence or 
absence of history of CV disease or history of hypertension, 
baseline statin use, or 0–1 versus ≥2 CV risk factors.
Safety
Canagliflozin 100 and 300 mg were generally well toler-
ated across subgroups by CV disease history or CV risk 
factors. The incidence of overall AEs, AEs leading to 
discontinuation, and serious AEs was similar with cana-




Fig. 2 Change from baseline in body weight at week 26. a History of CV disease, b history of hypertension, c baseline statin use, d number of CV 
risk factors. CV cardiovascular, LS least squares, SE standard error, CI confidence interval, PBO placebo, CANA canagliflozin
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Discussion
Patients with T2DM are at increased risk for CV dis-
ease, in part because of increased prevalence of comor-
bidities such as hypertension and dyslipidaemia [20, 
21]. The presence of CV disease and CV risk factors 
can complicate T2DM management [8]. This post hoc 
analysis evaluated the efficacy and safety of canagliflozin 
100 and 300  mg in patients with T2DM based on his-
tory of CV disease, history of hypertension, baseline use 
of statins, and the number of CV risk factors. To have a 
a b
c d
Fig. 3 Change from baseline in systolic BP at week 26. a History of CV disease, b history of hypertension, c baseline statin use, d number of CV risk 
factors. BP blood pressure, CV cardiovascular, LS least squares, SE standard error, CI confidence interval, PBO placebo, CANA canagliflozin
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sufficient sample size for analysis that was representative 
of a diverse population of patients with T2DM, data were 
pooled from four similarly designed 26-week, placebo-
controlled studies of canagliflozin. Results from these 
analyses showed that treatment with canagliflozin pro-
vided meaningful reductions in HbA1c, body weight, and 
systolic BP that were similar regardless of the presence or 
absence of history of CV disease, history of hypertension, 
baseline statin use, or number of CV risk factors. Across 
subgroups by CV disease history or risk factors, both 
doses of canagliflozin were generally well tolerated, with 
a safety profile consistent with that reported across clini-
cal trials of canagliflozin [14, 22, 23]. In the overall popu-
lation, the incidence of AEs was similar with canagliflozin 
and placebo; not surprisingly, an increased incidence of 
AEs related to the mechanism of SGLT2 inhibition (e.g., 
genital mycotic infections, osmotic diuresis–related AEs) 
was seen with canagliflozin [19, 22, 24].
Given the high burden of CV disease among patients 
with T2DM, some guidelines recommend a multifacto-
rial approach to managing T2DM [7, 25]. SGLT2 inhibi-
tors, such as canagliflozin, have been shown to provide 
significant improvements in HbA1c, body weight, and BP 
in a broad range of patients with T2DM [23], including 
older patient populations (≥65 and ≥75 years of age) who 
may be at elevated risk of CV disease [26, 27]. To improve 
dyslipidaemia, the European Society of Cardiology rec-
ommends statin therapy for all patients with T2DM over 
40 years of age and for selected younger patients with ele-
vated CV disease risk [28]. Despite this recommendation, 
less than 50% of patients in this population were using 
statins at baseline. Statin therapy has been shown to be 
associated with increased HbA1c levels in patients with 
T2DM [29–32]. In the current analysis, canagliflozin 
treatment provided clinically meaningful improvements 
in HbA1c in patients with T2DM, regardless of baseline 
statin use.
Choice of AHAs may be limited for patients with 
T2DM and CV disease history and CV risk factors 
based on data suggesting an increased risk for negative 
CV outcomes with some agents [9–11]. There is a grow-
ing body of evidence that SGLT2 inhibitors can provide 
cardiometabolic benefits beyond glycaemic control. In 
the EMPA-REG OUTCOME trial, empagliflozin showed 
a significant reduction in the risk of CV death and heart 
failure hospitalisation compared with placebo [33]. Based 
on these results, the US Food and Drug Administration 
recently approved a new indication for empagliflozin to 
reduce the risk of CV death in adult patients with T2DM 
and established CV disease [34]. It is hypothesised that 
the mechanism for the cardioprotective effect seen with 
empagliflozin is likely relevant for the entire SGLT2 
inhibitor class due to improvements in glycaemic control, 
as well as BP and body weight reduction via induction 
of a mild osmotic diuresis, increased natriuresis, and 
net caloric loss [35–38]. In particular, it has been postu-
lated that the increased osmotic diuresis associated with 
SGLT2 inhibition may help to reduce cardiac workload 
via reductions in BP and intravascular volume [37, 38]. 
Results from the ongoing CANVAS Program [39], includ-
ing CANagliflozin cardioVascular Assessment Study 
(CANVAS; ClinicalTrials.gov Identifier: NCT01032629) 
and CANVAS-R (renal endpoints; NCT01989754) [40, 
41], will provide evidence on the CV safety and efficacy of 
canagliflozin in more than 10,000 patients with CV dis-
ease history or CV risk factors upon completion in 2017 
and will confirm whether the CV benefits observed with 
empagliflozin support a class effect. In addition, a sepa-
rate study is underway to evaluate the effects of canagli-
flozin versus glimepiride in Japanese patients with T2DM 
and chronic heart failure [42].
Due to the post hoc nature of these analyses, the cur-
rent study was limited by a lack of prespecified statistical 
testing across subgroups. However, calculated 95% CIs 
allowed for descriptive comparisons for treatment with 
both canagliflozin doses and placebo. Comparisons were 
also limited by the small number of patients with CV dis-
ease history at baseline, which was not surprising for this 
general population of patients with T2DM. Nevertheless, 
the subgroup analysis results were generally consistent 
with those seen in the overall pooled population [24]. 
Similar analyses using longer-term efficacy and safety 
data could provide additional insight into the durability 
of benefits and risks associated with canagliflozin based 
on CV disease history and CV risk factors.
Conclusions
Treatment with canagliflozin 100 and 300  mg provided 
consistent reductions in HbA1c, body weight, and sys-
tolic BP, and was generally well tolerated over 26 weeks 
of treatment in patients with T2DM, regardless of CV 
disease history or CV risk factors. These findings are 
noteworthy given the high burden of CV disease among 
patients with T2DM and the need for diabetes therapies 
that are safe and efficacious in patients with T2DM and 
CV disease.
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